CoChat

Large-vessel vasculitis

Open access
Pugh, Dan, Karabayas, Maira, Basu, Neil, Cid, Maria C., Goel, Ruchika, Goodyear, Carl S., Grayson, Peter C., McAdoo, Stephen P., Mason, Justin C., Owen, Catherine, Weyand, Cornelia M., Youngstein, Taryn, Dhaun, Neeraj · 2022 · Nature Reviews Disease Primers
Cited by 251

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Large-vessel vasculitis is the most common primary vasculitis in adults, manifesting as inflammation of the aorta and its major branches. This Primer reviews the epidemiology, pathophysiology, diagnosis and management of this disease, highlights its effects on patient quality of life, and discusses future research questions. Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches and is the most common primary vasculitis in adults. LVV comprises two distinct conditions, giant cell arteritis and Takayasu arteritis, although the phenotypic spectrum of primary LVV is complex. Non-specific symptoms often predominate and so patients with LVV present to a range of health-care providers and settings. Rapid diagnosis, specialist referral and early treatment are key to good patient outcomes. Unfortunately, disease relapse remains common and chronic vascular complications are a source of considerable morbidity. Although accurate monitoring of disease activity is challenging, progress in vascular imaging techniques and the measurement of laboratory biomarkers may facilitate better matching of treatment intensity with disease activity. Further, advances in our understanding of disease pathophysiology have paved the way for novel biologic treatments that target important mediators of disease in both giant cell arteritis and Takayasu arteritis. This work has highlighted the substantial heterogeneity present within LVV and the importance of an individualized therapeutic approach. Future work will focus on understanding the mechanisms of persisting vascular inflammation, which will inform the development of increasingly sophisticated imaging technologies. Together, these will enable better disease prognostication, limit treatment-associated adverse effects, and facilitate targeted development and use of novel therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41572-021-00327-5

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 251

Metadata

Authors
Pugh, D., Karabayas, M., Basu, N., Cid, M. C., Goel, R., Goodyear, C. S., Grayson, P. C., McAdoo, S. P., Mason, J. C., Owen, C., Weyand, C. M., Youngstein, T., & Dhaun, N.
Venue
Nature Reviews Disease Primers
Published
2022-01-06
Volume
7
Issue
1
Pages
93-93
ISSN
2056-676X (ISSN-L)
OpenAlex
W4205806163
Cited by
251
References
3
FWCI
13.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Large-vessel vasculitis. https://app.cochat.ai/papers/10.1038/s41572-021-00327-5
The paper
Pugh, D., Karabayas, M., Basu, N., Cid, M. C., Goel, R., Goodyear, C. S., Grayson, P. C., McAdoo, S. P., Mason, J. C., Owen, C., Weyand, C. M., Youngstein, T., & Dhaun, N. (2022). Large-vessel vasculitis. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-021-00327-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.